Polycystic ovary syndrome (PCOS) does increase the risk of certain cancers, most notably endometrial cancer. Women with PCOS are roughly four times more likely to develop endometrial cancer than women without the condition, and that risk climbs even higher in premenopausal women. The connection to other cancers is more nuanced, with some risks modestly elevated and others showing no clear link at all.
Endometrial Cancer: The Strongest Link
The connection between PCOS and endometrial cancer is the most well-established and the most significant. A large meta-analysis found that women with PCOS had four times the odds of developing endometrial cancer compared to women without it. When researchers narrowed the analysis to premenopausal women only, the odds jumped to five times higher.
What makes this especially important is the age at which it can develop. Endometrial cancer in the general population typically appears between ages 60 and 70. In women with PCOS, cases have been documented as early as the late 20s, with one study reporting an average age of onset around 35. That’s decades earlier than expected, and it means younger women with PCOS should take irregular periods seriously rather than writing them off as just a PCOS symptom.
Why PCOS Drives Endometrial Risk
The primary culprit is chronic anovulation, meaning your ovaries don’t release an egg during most cycles. In a typical menstrual cycle, ovulation triggers progesterone production, which balances out estrogen and causes the uterine lining to shed. When you don’t ovulate, progesterone never kicks in, and the uterine lining is exposed to estrogen month after month without a counterbalance. This is called “unopposed estrogen,” and it causes the lining to keep thickening, which can eventually lead to abnormal cell growth and cancer.
Two other features of PCOS compound this problem. Insulin resistance, which affects the majority of women with the condition, leads to chronically high insulin levels. Elevated insulin activates cell growth pathways that help abnormal cells survive and multiply. On top of that, PCOS creates a state of chronic low-grade inflammation throughout the body, and sustained inflammation is a recognized driver of cancer development across many organ systems. So the endometrium is hit from multiple directions: constant estrogen stimulation, insulin-driven cell growth, and an inflammatory environment.
Ovarian and Breast Cancer Risk
The picture for ovarian cancer is complicated. Some observational studies have found a modest increase in ovarian cancer risk among women with PCOS. One meta-analysis estimated the odds were about 1.3 times higher than in women without the condition. However, a genetic study that used a different approach, looking at inherited PCOS risk rather than diagnosed cases, actually found the opposite: women genetically predisposed to PCOS had a slightly lower risk of invasive ovarian cancer, particularly a subtype called endometrioid ovarian cancer, where risk dropped by about 23%. These conflicting results suggest that any ovarian cancer link, if it exists, is small and possibly driven by shared risk factors like obesity rather than PCOS itself.
For breast cancer, the evidence is more straightforward. Multiple large meta-analyses have consistently found no significant association between PCOS and breast cancer. Despite the hormonal disruptions that characterize PCOS, the condition does not appear to raise breast cancer risk in any meaningful way.
Protecting Your Endometrium
The most effective strategy for reducing endometrial cancer risk in PCOS centers on one goal: making sure your uterine lining sheds regularly. If you’re not ovulating on your own, your body needs help providing that progesterone signal.
Combined hormonal birth control pills are the most commonly prescribed option. They supply both estrogen and progesterone in a cycle that triggers regular withdrawal bleeds, preventing the lining from building up unchecked. The 2023 international evidence-based guidelines for PCOS also note that progestin-only oral contraceptives can be considered for endometrial protection. For women not on hormonal contraception, doctors sometimes prescribe cyclical progestin courses to induce a bleed every one to three months.
Addressing insulin resistance also matters. Losing even a modest amount of weight, around 5 to 10 percent of body weight, can restore ovulation in some women and lower circulating insulin levels. Regular physical activity independently improves insulin sensitivity. While metformin is widely used for insulin resistance in PCOS, current evidence from meta-analyses has not shown a clear reduction in gynecological cancer risk from its use alone.
What the Risk Actually Means in Practice
A four- or five-fold increase in risk sounds alarming, but it helps to put the baseline numbers in perspective. Endometrial cancer is relatively uncommon in young women. If the baseline risk for a premenopausal woman in a given year is very low, multiplying it by five still results in a small absolute number. The lifetime risk of endometrial cancer for all women in the U.S. is about 3 percent. Even with PCOS pushing that higher, the majority of women with the condition will not develop it.
That said, the risk is real and preventable. The single most important warning sign is prolonged absence of periods. If you go several months without a bleed and you’re not pregnant, your uterine lining is accumulating without shedding. Abnormal bleeding patterns, such as very heavy or prolonged periods after long gaps, can also signal that the lining has thickened abnormally. Keeping your cycles regulated, staying physically active, and managing your weight are the most practical steps you can take to keep this risk low over the long term.